Company: OXBRW
Filing Date: 2025-02-26
Form Type: 424B5
Source: 0001493152-25-008248
Chunk: 10

Company: OXBRIDGE RE HOLDINGS Ltd
Filing Date: 2025-02-26
Form: 424B5
Chunk 10
---
 about investing in our shares, you should carefully consider the specific risk factors discussed below as well as the risk factors discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings we make under the Exchange Act, each of which is incorporated by reference in this prospectus supplement in its entirety, together with all of the other information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, the documents incorporated by reference herein and therein, and any related free writing prospectuses we may issue. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. If any such risks actually occur, our business, financial condition, or results of operations could be materially and adversely affected. In such cases, the trading price of our ordinary shares could decline, and you may lose all or part of your investment.

Risks Relating to this Offering

Management will have broad discretion as to the use of the proceeds from this offering, and we may use the proceeds in ways in which you and other shareholders may disagree.

We have not designated any amount of the net proceeds we will receive from this offering for any particular purpose. Accordingly, our management will have broad discretion as to the application of such net proceeds and could use them for purposes other than those contemplated at the time of this offering. Our shareholders may not agree with the manner in which our management chooses to allocate and spend such net proceeds. In addition, such proceeds could be applied in ways that do not improve our operating results or increase the value of your investment. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development and commercialization of our products and cause the price of our ordinary shares to decline.

You will experience immediate and substantial dilution in the net tangible book value per ordinary share in this offering.

The effective price per ordinary share is substantially higher than the net tangible book value per ordinary shares with respect to shares outstanding prior to this offering. Based on the combined offering price of each ordinary share and accompanying ordinary share warrants of $4.25, and our net tangible book value per ordinary share as of September 30, 2024, if you purchase ordinary shares in this offering, you will suffer immediate and substantial dilution of $3